Endocrine Abstracts

Zoledronic acid (ZA) treatment increases bone mineral density (BMD), decreases bone turnover markers and reduces the risk of fractures in patients with osteoporosis (1).Objective: Observe and quantify the changes in BMD and bone turnover markers in postmenopausal osteoporosis (PO) patients treated annually with zoledronic acid 5 mg intravenously.Material and Methods: Medical records (MR) of PO patients whom received ZA from 2007 to...